NexImmune, Inc. announced that, in order to reduce its cash expenditures while continuing to pursue its existing strategic plan, its Board of Directors approved and its management is implementing an approximately 53% reduction in workforce, designed to reduce costs and extend the Company?s cash. The realignment will reduce the Company?s workforce from 47 to 22 full-time employees as of September 5, 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.483 USD | +3.04% | +11.62% | +56.87% |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 16 | NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
1st Jan change | Capi. | |
---|---|---|
+56.87% | 4.63M | |
+2.68% | 108B | |
+9.24% | 105B | |
+0.03% | 23.46B | |
-14.38% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-7.52% | 17.19B | |
+6.39% | 13.99B | |
+35.51% | 12.53B |
- Stock Market
- Equities
- NEXI Stock
- News NexImmune, Inc.
- NexImmune, Inc. Announces Workforce Reduction to Enable Continued AIMTM Nanoparticle Platform Development Strategy